Cover Image
市場調查報告書

表皮性卵巢癌:開發中產品分析

Epithelial Ovarian Cancer - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 247793
出版日期 內容資訊 英文 479 Pages
訂單完成後即時交付
價格
Back to Top
表皮性卵巢癌:開發中產品分析 Epithelial Ovarian Cancer - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 479 Pages
簡介

所謂表皮性卵巢癌,是覆蓋卵巢的組織內部出現惡性腫瘤(癌症)細胞的疾病。卵巢癌,初期階段沒有特別症狀,症狀呈現時常常已經惡化了。主要的症狀為腹部的疼痛和腫脹,子宮內部的疼痛,消化管的失調(氣、膨脹滿感、便秘)等。表皮性卵巢癌的治療方法,有外科手術和放射治療,化療等各種手段。

本報告提供全球各國治療表皮性卵巢癌所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

表皮性卵巢癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

表皮性卵巢癌:企業開發中的治療藥

表皮性卵巢癌:大學/機關研究中的治療藥

表皮性卵巢癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

表皮性卵巢癌:企業開發中的產品

表皮性卵巢癌:大學/機關研究中的產品

表皮性卵巢癌治療藥的開發企業

  • AbbVie Inc.
  • Adaptimmune Therapeutics Plc
  • Amgen Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc 38
  • Atara Biotherapeutics, Inc.
  • Bayer AG
  • BioNumerik Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Celldex Therapeutics, Inc.
  • Celon Pharma Sp. z o.o.
  • Celsion Corporation
  • CerRx, Inc.
  • Cerulean Pharma, Inc.
  • Clovis Oncology, Inc.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • Eisai
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genentech, Inc.
  • Genor BioPharma Co., Ltd.
  • Glycotope GmbH
  • Ignyta, Inc.
  • ImmunoGen, Inc.
  • Incyte Corporation
  • Innate Immunotherapeutics Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Mabion SA.
  • MabVax Therapeutics Holdings, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oasmia Pharmaceutical AB
  • OBI Pharma, Inc.
  • Oncobiologics, Inc.
  • Oncolix, Inc.
  • Oncolytics Biotech Inc.
  • 大塚集團
  • Oxford BioMedica Plc
  • OXiGENE, Inc.
  • Pfizer Inc 78
  • Pharma Mar, S.A.
  • Pharmacyclics, Inc.
  • Prima BioMed Ltd.
  • PsiOxus Therapeutics Limited
  • Quest PharmaTech Inc.
  • Sanofi
  • Sanofi Pasteur SA
  • Shenzen SiBiono GeneTech Co., Ltd.
  • Sotio a.s
  • Synta Pharmaceuticals Corp.
  • Tara Immuno-Oncology Therapeutics LLC
  • Tesaro, Inc.
  • TetraLogic Pharmaceuticals
  • Tyrogenex, Inc.
  • VentiRx Pharmaceuticals, Inc.
  • ViiV Healthcare Limited
  • Vyriad

表皮性卵巢癌:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

表皮性卵巢癌:最近的開發平台趨勢

表皮性卵巢癌:暫停中的計劃

表皮性卵巢癌:開發中止的產品

表皮性卵巢癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8000IDB

Summary

Global Markets Direct's, 'Epithelial Ovarian Cancer - Pipeline Review, H1 2016', provides an overview of the Epithelial Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
  • The report reviews pipeline therapeutics for Epithelial Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Epithelial Ovarian Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Epithelial Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Epithelial Ovarian Cancer Overview
  • Therapeutics Development
  • Epithelial Ovarian Cancer - Therapeutics under Development by Companies
  • Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
  • Epithelial Ovarian Cancer - Pipeline Products Glance
  • Epithelial Ovarian Cancer - Products under Development by Companies
  • Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes
  • Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development
  • Epithelial Ovarian Cancer - Therapeutics Assessment
  • Drug Profiles
  • Epithelial Ovarian Cancer - Recent Pipeline Updates
  • Epithelial Ovarian Cancer - Dormant Projects
  • Epithelial Ovarian Cancer - Discontinued Products
  • Epithelial Ovarian Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Epithelial Ovarian Cancer, H1 2016
  • Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Bayer AG, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Celsion Corporation, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by CerRx, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by EirGenix Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Genentech, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Ignyta, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Incyte Corporation, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Juno Therapeutics Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Mabion SA, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by MedImmune, LLC, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Mycenax Biotech Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Novartis AG, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by OBI Pharma, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Oncobiologics, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Oncolix, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica Plc, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by OXiGENE, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Pfizer Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Quest PharmaTech Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Sanofi, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Tesaro, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Tyrogenex, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016
  • Epithelial Ovarian Cancer - Pipeline by ViiV Healthcare Limited, H1 2016
  • Epithelial Ovarian Cancer - Pipeline by Vyriad, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Epithelial Ovarian Cancer - Dormant Projects, H1 2016
  • Epithelial Ovarian Cancer - Dormant Projects (Contd..1), H1 2016
  • Epithelial Ovarian Cancer - Dormant Projects (Contd..2), H1 2016
  • Epithelial Ovarian Cancer - Dormant Projects (Contd..3), H1 2016
  • Epithelial Ovarian Cancer - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Epithelial Ovarian Cancer, H1 2016
  • Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top